News & Event
- Home
- News
- News & Event
Prestige BioPharma opened its Innovative Discovery Center in Busan
Prestige BioPharma, headquartered in Singapore, held an opening ceremony of its new R&D control center, the Prestige BioPharma Innovative Discovery Center (IDC), in Myeongji International City, Busan on November 13.
The opening ceremony drew about 200 attendees, including executives from Prestige BioPharma, government representatives, and officials from the Ministry of Trade, Industry, and Energy, the Busan Metropolitan City, and Gangseo-gu Office.
According to Busan-si, the Prestige BioPharma IDC, which was designated as an “Advanced Investment Zone" by the MOTIE, is a bio pharmaceutical R&D center, has been completed into a building of one basement floor and six above-floors on 31,000 square meters site.
Prestige BioPharma IDC plans that the opening of the IDC will serve as a final piece of completing the company’s full value chain system, covering antibody drug development, clinical trials, commercialization, and production.
At the IDC, Prestige BioPharma will conduct research on its pipeline of 16 antibody drug candidates, including PBP1510, a pancreatic cancer antibody therapeutic candidate currently in a clinical trials and PBP1710, which is in preclinical stages. IDC also aims to pioneer new antibody-drug conjugate modalities.
To strengthen its position as a center of new drug development, the Busan IDC will have an open innovation space on the second floor to create the synergy effect through joint R&D with bioengineering startups, and university-affiliated research centers.
ccho@yna.co.kr
Source Text
** This article was translated from Korean.
Date
2024.11.18
Views
171
According to Yonhap News,
Prestige BioPharma, headquartered in Singapore, held an opening ceremony of its new R&D control center, the Prestige BioPharma Innovative Discovery Center (IDC), in Myeongji International City, Busan on November 13.
The opening ceremony drew about 200 attendees, including executives from Prestige BioPharma, government representatives, and officials from the Ministry of Trade, Industry, and Energy, the Busan Metropolitan City, and Gangseo-gu Office.
According to Busan-si, the Prestige BioPharma IDC, which was designated as an “Advanced Investment Zone" by the MOTIE, is a bio pharmaceutical R&D center, has been completed into a building of one basement floor and six above-floors on 31,000 square meters site.
Prestige BioPharma IDC plans that the opening of the IDC will serve as a final piece of completing the company’s full value chain system, covering antibody drug development, clinical trials, commercialization, and production.
At the IDC, Prestige BioPharma will conduct research on its pipeline of 16 antibody drug candidates, including PBP1510, a pancreatic cancer antibody therapeutic candidate currently in a clinical trials and PBP1710, which is in preclinical stages. IDC also aims to pioneer new antibody-drug conjugate modalities.
To strengthen its position as a center of new drug development, the Busan IDC will have an open innovation space on the second floor to create the synergy effect through joint R&D with bioengineering startups, and university-affiliated research centers.
ccho@yna.co.kr
Source Text
Copyrights Yonhap News. All Rights Reserved.
Reprint or redistribution without permission is prohibited.
Source: Yonhap News (November 14, 2024)
** This article was translated from Korean.